Cargando…

外周血游离DNA的动态变化预测TKI治疗EGFR突变肺腺癌患者的疗效

BACKGROUND AND OBJECTIVE: The tyrosine kinase inhibitors (TKI) treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation may have a positive effect, but most patients may develop drug resistance, therefore, the detection of the developing time in drug resi...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754570/
https://www.ncbi.nlm.nih.gov/pubmed/31526460
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.09.03